New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic.

Autor:	Havrdova E; Department of Neurology, Charles University, Praha, Czech Republic., Kobelt G; European Health Economics, Mulhouse, France., Berg J; Mapi Group, Stockholm, Sweden., Capsa D; Mapi Group, Stockholm, Sweden., Gannedahl M; Mapi Group, Stockholm, Sweden., Doležal T; Value Outcomes, Praha, Czech Republic.
Jazyk:	angličtina
Zdroj:	Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2017 Aug; Vol. 23 (2_suppl), pp. 41-52.
DOI:	10.1177/1352458517708117
Abstrakt:	Introduction: In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and Methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, in the societal perspective, in CZK 2015. Results: A total of 747 patients (mean age 47 years) participated; 86% were below retirement age and of these, 49% were employed. Employment was related to disease severity, and MS affected productivity at work for 82% of those working. Overall, 92% and 66% of patients experienced fatigue and cognitive difficulties as a problem. Mean utility and annual costs were 0.832 and 257,000CZK at Expanded Disability Status Scale (EDSS) 0-3, 0.530 and 425,500CZK at EDSS 4-6.5 and 0.141 and 489,000CZK at EDSS 7-9. The average cost of a relapse was estimated at 12,600CZK. Conclusion: This study provides current data on MS in the Czech Republic that are important for the development of health policies.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu